Sign up Australia
Proactive Investors - Run By Investors For Investors

Phosphagenics in U.S. research deal to tackle bacterial mastitis infection in cows

Phosphagenics in U.S. research deal to tackle bacterial mastitis infection in cows

Phosphagenics (ASX: POH) with the U.S. Department of Agriculture’s Agricultural Research Service (ARS) to develop and trial products targeting the serious bacterial infection mastitis in dairy cows.

In the U.S. alone, economic losses resulting from mastitis, which affects 15% of the world’s dairy herd at any given time, are estimated at US$2 billion per annum.

Under the agreement, Phosphagenics and ARS will formulate and evaluate products containing active ingredients in combination with the company’s TPM® delivery technology to enable superior absorption and efficacy.

The products will include the formulation previously trialled by Phosphagenics with good results, as well as a formulation containing a Vitamin D derivative.   

A preliminary study conducted by ARS in 2012 demonstrated that directly infusing the Vitamin D derivative into infected quarters of the mammary gland in infected dairy cows was able to significantly lower bacteria counts and clinical symptoms of mastitis.

Treated cows also exhibited superior milk production.

Trials will begin in mid-2013 and will be conducted in the U.S. by the ARS.

Researchers will examine the effects and efficacy of the TPM® formulated products delivered via intramammary infusion using a protocol developed by ARS.   


Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.

Register here to be notified of future POH Company articles
View full POH profile

Phosphagenics Timeline

Related Articles

Pills and the EU stars
July 19 2016
Alliance's swoop for Sinclair Healthcare Products in December helped it rack up first-half sales of £46.4mln
Concept of a DNA strand
September 13 2016
Proactive Investors takes a closer look at an AIM-listed biotech firm that is making incredible advances altering the inner workings of the human body to tackle deadly diseases.
November 30 2016
The focus initially will be previously-approved indications for adolescent obesity along with new treatment areas non-alcoholic fatty liver disease and for non-alcoholic steatohepatitis

© Proactive Investors 2016

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.